New to 2018: The role of artificial intelligence in drug discovery
SMi Reports: SMi’s 2nd annual Drug Discovery conference, taking place in London on 21 and 22 March 2018, will discuss the role of artificial intelligence in drug discovery.
List view / Grid view
SMi Reports: SMi’s 2nd annual Drug Discovery conference, taking place in London on 21 and 22 March 2018, will discuss the role of artificial intelligence in drug discovery.
Johns Hopkins scientists have used a form of artificial intelligence to create a map that compares types of cellular receptors, the chemical ‘antennas’ on the surface of immune system T-cells.
A new race is well underway involving big pharma and big data companies to see who can most effectively mine the new massive data using artificial intelligence (AI). The aim: reducing costs by using targeted in silico analysis, reducing in vitro and in vivo screening, and reviewing huge quantities of…
Non-invasive diagnostic tool measures circulating microRNAs to predict ovarian cancer with specificity...
Scientists have used artificial intelligence techniques and big data to develop an algorithm capable of recognising the signatures of dementia two years before its onset, using a single amyloid PET scan...
A new scorpion-milking robot designed to extract venom could replace the traditional manual method.
The wealth of data produced by the European Commission's Joint Research Centre (JRC) is now available to external users.
A mixed reality system which allows medical practitioners to view and interact with virtual replicas of patients’ organs, bones or body parts is being developed by academics.
Radisens Diagnostics, an Irish medtech business, is aiming to raise £22 million to bring its innovative diabetes management platform to market...
AMI has released the full version of HCC Coding as part of the EMscribe suite of tools in support of medical records processing and abstraction.
Sophia Genetics injects artificial intelligence in liquid biopsies to accelerate early detection of cancer and monitor treatments’ effectiveness.
SOPHiA AI demystifies the secrets of the exome, home to 85% of disease-causing genetic variants. Clinicians can now get highly accurate results to diagnose patients for rare hereditary disorders.
Exscientia has agreed a strategic research collaboration, and licence option agreement with Sanofi in the high-interest area of metabolic disease.
BenevolentAI, a British artificial intelligence company, has partnered with MRC Technology (MRCT), a medical research charity, to explore drug discovery initiatives in the field of small molecules and antibodies.
Orbital Media and the University of Essex are joining forces to use artificial intelligence to save the NHS millions of pounds per year by creating automated online GPs to revolutionise the way patients are treated.